Infection, Bacterial
2
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
1 program1
ATx201 dermal formulations 2%Phase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
UNION therapeuticsATx201 dermal formulations 2%
XenotheraExperimental
Alliance PharmaceuticalsOptimised kangaroo care
Clinical Trials (3)
Total enrollment: 3,178 patients across 3 trials
Evaluation of ATx201 as a Topical Antibiotic Agent
Start: Dec 2016Est. completion: Mar 201873 patients
Phase 1/2Completed
A First-in-Human Study With XAB05 in Healthy Subjects
Start: Jan 2022Est. completion: May 202225 patients
Phase 1Completed
Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.
Start: May 2024Est. completion: May 20263,080 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 3,178 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.